June 14, 2016
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Onconova Announces Presentation of Clinical Data from Oral
Rigosertib/Azacitidine Combination Study in Higher-Risk Myelodysplastic
Syndromes at EHA Annual Meeting
TOKYO, Japan, June 14, 2016 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo,“SymBio”) announced today that its U.S. partner, Onconova Therapeutics, Inc.
(Headquarters: Newtown, PA, “Onconova”) announced on June 13, 2016 (EST) thepresentation of interim data by U.S. and European Onconova collaborators from theongoing fully-enrolled Phase 2 clinical trial of oral rigosertib/azacitidine combination inpatients with either first- or second-line higher-risk myelodysplastic syndromes at theannual European Hematology Association (EHA) meeting in Denmark, which took place
June 9 – 11, 2016.
Onconova is finalizing such results to initiate the end of Phase 2 trial discussions with U.S.
and European regulatory agencies to define the next steps in the development plan for thiscombination therapy.
SymBio obtained the licensing rights for rigosertib in July, 2011 and retains thedevelopment rights for Japan and Korea.

For more details in this press release, please visit Onconova’s homepage at
http://investor.onconova.com/releases.cfm
This event will not impact the Company’s current financial forecast.

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125

About Myelodysplastic Syndromes (MDS)MDS patients often require frequent blood transfusions due to the development of severe
anemia (decrease in the number of red blood cells), with a high rate of progression to acute
myelogenous leukemia (AML). There are an estimated 11,000 MDS patients in Japanalone, with the number of cases expected to increase as the population ages. MDS andAML are widely recognized as two blood disorders that are difficult to manage given thelimited therapeutic options available for patients, particularly for patients who have adrug-resistant form of the disease. A high unmet medical need clearly exists for theestablishment of new effective therapies to treat both lower-risk MDS and higher-risk
MDS.
About Onconova Therapeutics, Inc.
Onconova Therapeutics is a Phase 3 clinical-stage biopharmaceutical company focused on
discovering and developing novel products to treat cancer. Onconova's clinical andpre-clinical stage drug development candidates are derived from its extensive chemicallibrary and are designed to work against specific cellular pathways that are important incancer cells, while causing minimal damage to normal cells. In addition to rigosertib, theCompany's most advanced product candidate, two other candidates are clinical stage, andseveral candidates are in pre-clinical stages.
For more information, please visit http://www.onconova.com.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March, 2005, by Fuminori Yoshida
who previously served concurrently as Corporate VP of Amgen Inc. and founding Presidentof Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in
the United States, called SymBio Pharma USA, Inc. (Headquarters: Menlo Park,California, USA, President: Mr. Fuminori Yoshida).
The Company’s underlying corporate mission is to “deliver hope to patients in need” as it
aspires to be a leading global specialty biopharmaceutical company dedicated toaddressing underserved medical needs with main therapeutic focus in oncology,
hematology and pain management.